Shanghai Institute of Material Medical Chinese Academy of Sciences

Biography

EDUCATION
09/1994–09/1998 Zhangzhou University B.S. degree
09/1998–09/2003 Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Ph.D degree

WORK EXPERIENCE
08/2003–03/2005 Mayo Clinic, Jacksonville, Florida, USA, Research Fellow
04/2005–02/2007 Wake Forest University, North Carolina, USA, Research Fellow/Associate
02/2007–06/2009 Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Associate Professor
06/2009–now Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Professor, Principle Investigator

Research Directions

Mainly focuses on study of pathogenesis of Alzheimer’s disease (AD) and discovery of novel therapeutic strategies for AD, vascular dementia (VaD) and ischemic stroke. The recent research interestsof Dr. Zhang’s group are to identify and validate key drug targetsagainst Aβ oligomer associated aberrant signaling pathway, as well as developing potential drug candidates for the treatment of AD or ischemic stroke based on eitheractive natural productsor important therapeutic targets (AChE, Aβ , PSD95-nNOS, SIRT).

Grants & Research Projects

Shanghai Science and Technology Development Funds, Molecular mechanisms involved between Aβ and mitochondrial function, Project Leader, 2010.4-2012.4
National Natural Science Foundation of China, Relationship between intracellular Aβ and mitochondrial function in APP transgenic mice and therapeutic strategies. Project Leader, 2009.1-2011.12
National Natural Science Foundation of China, Role of Insulin/IGF-1 Signaling in the pathogenesis of Alzheimer’ s disease and associated therapeutic strategies, Project Leader, 2012.1-2015.12
National Science & Technology Major Project, Key New Drug Creation and Manufacturing Program” of China, Research in novel anti-Alzheimer’s disease candidates？YLV-1, Project Leader, 2009.0-2010.12
National Science & Technology Major Project, Key New Drug Creation and Manufacturing Program” of China, Preclinical Research in novel anti-Alzheimer’s disease candidates？YLV-1, Project Leader 2013.1-2015.12

Achievements

Published 58 papers in SCI cited journals (Trends Pharmacol Sin, Neurobiol Aging, Free RadicBiol& Med, J Alzheimer Dis, et al), applied 14 invention patents with 4 authorized.

morefold

Social Titles

Anti-aging and Alzheimer's Professional Committee, Chinese Pharmaceutical Society, committee member
Acta Pharmacologica Sinica, Member of Editorial board
Journal of Alzheimer’ s disease, Member of Editorial board

morefold

Awards & Honors

2010, Chinese Pharmaceutical Society Sevier Young Faculty Award
2010, SA-SIBS Outstanding Youth Talent Scholarship

morefold

Pubilcations

Full Publication List

Selected Publications

（Representative Publications 2015-2020）

1.Feng HX, Hu LH, Zhu HW, Tao LX, Wu L, Zhao QY, Gao YM, Gong Q, Mao F, Li XK, Zhou H*, Li J*, Zhang HY*. Repurposing antimycotic ciclopirox olamine as a promising anti-Ischemic stroke agent. Acta Pharm Sin B. 2020;10:434-446.

2.Hu LH, Feng HX, Zhang HG, Yu SD, Zhao QY, Wang W, Bao FX, Ding X, Hu JJ, Wang MJ, Xu YX, Wu ZR, Li XK, Tang Y, Mao F*, Chen XY, Zhang HY*, Li J*. Development of novel N-hydroxypyridone derivatives as potential anti-ischemic stroke agents. J Med Chem. 2020;63:1051-1067.

3.Bao FX, Tao LX*, Zhang HY*. Neuroprotective Effect of Natural Alkaloid Fangchinoline Against Oxidative Glutamate Toxicity: Involvement of Keap1-Nrf2 Axis Regulation. Cell Mol Neurobiol. 2019;39:1177-1186.

4.Feng HX, Li CP, Shu SJ, Liu H*, Zhang HY*. A11, a novel diaryl acylhydrazone derivative, exerts neuroprotection against ischemic injury in vitro and in vivo. Acta Pharmacol Sin. 2019;40:160-169

5.Fu W, Yan C, Guo ZQ, Zhang J, Zhang HY*, Tian H*, Zhu WH*. Rational Design of Near-Infrared Aggregation-Induced-Emission-Active Probes: In Situ Mapping of Amyloid-β Plaques with Ultrasensitivity and High-Fidelity. J Am Chem Soc. 2019;141:3171-3177.

6.Xu YX, Zhang J, Wang H, Mao F, Bao KT, Liu WW, Zhu J, Li XK*, Zhang HY*, Li J*. Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential Anti-Alzheimer's Disease Agents. ACS Chem Neurosci. 2019;10:482-496.

7.Huang XT, Liu X, Ye CY, Tao LX, Zhou H*, Zhang HY*. Iron-induced energy supply deficiency and mitochondrial fragmentation in neurons. J Neurochem. 2018;147:816-830.

8.Chen YT, Chen WY, Huang XT, Xu YC*, Zhang HY*. Iron dysregulates APP processing accompanying with sAPPα cellular retention and β-secretase inhibition in rat cortical neurons. Acta Pharmacol Sin. 2018;39:177-183.

9.Ren W, Zhang JJ, Peng C, Xiang HJ, Chen J1, Peng CY, Zhu WL, Huang RM*, Zhang HY*, Hu YH*. Fluorescent Imaging of β-Amyloid Using BODIPY Based Near-Infrared Off-On Fluorescent Probe. Bioconjug Chem. 2018;29:3459-3466.

10.Xu YX, Wang H, Li XK, Dong SN, Liu WW, Gong Q, Wang TD, Tang Y, Zhu J, Li J*, Zhang HY*, Mao F*. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem. 2018;143:33-47.

11.Ni W, Wang H, Li XK, Zheng XY, Wang MJ, Zhang J, Gong Q, Ling DZ, Mao F*, Zhang HY*, Li J*. Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5). ACS Chem Neurosci. 2018;9:1625-1636.

12.Mao F, Wang H, Ni W, Zheng XY, Wang MJ, Bao KT, Ling DZ, Li XK, Xu YX, Zhang HY*, Li J*. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease. ACS Chem Neurosci. 2018;9:328-345.

13.Wu L, Wang HM, Li JL, Feng HX, Zhao WM, Zhang HY*. Dual anti-ischemic effects of rosmarinic acid n-butyl ester via alleviation of DAPK-p53-mediated neuronal damage and microglial inflammation. Acta Pharmacol Sin. 2017; 38: 459-468.

14.Li XK, Wang H, Xu YX, Liu WW, Gong Q, Wang W, Qiu XX, Zhu J, Mao F, Zhang HY*, Li J*. Novel Vilazodone-Tacrine Hybrids as Potential Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease Accompanied with Depression: Design, Synthesis, and Biological Evaluation. ACS Chem Neurosci. 2017;8:2708-2721.

15.Ren W, Xu M, Liang SH, Xiang H, Tang L, Zhang M, Ding D, Li X, Zhang H*, Hu Y*. Discovery of a novel fluorescent probe for the sensitive detection of β-amyloid deposits. Biosens Bioelectron. 2016;75:136-41.

16.Li X, Wang H, Lu Z, Zheng X, Ni W, Zhu J, Fu Y, Lian F, Zhang N, Li J*, Zhang H*, Mao F*. Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents. J Med Chem. 2016;59:8326-44.

17.Tang Y, Xiong J, Zhang JJ, Wang W, Zhang HY*, Hu JF*. Annotinolides A-C, Three Lycopodane-Derived 8,5-Lactones with Polycyclic Skeletons from Lycopodium annotinum. Org Lett. 2016;18:4376-9.

18.Li JL, Wu L, Wu J, Feng HX, Wang HM, Fu Y, Zhang RJ, Zhang HY*, Zhao WM*. Caffeoyl Triterpenoid Esters as Potential Anti-ischemic Stroke Agents from Celastrus orbiculatus. J Nat Prod. 2016;79:2774-2779.

19.Ye CY, Lei Y, Tang XC, Zhang HY*. Donepezil Attenuates A?-associated Mitochondrial Dysfunction and Reduces Mitochondrial A accumulation in vivo and in vitro. Neuropharmacology. 2015;95:29-36.

20.Ruan Z, Wang HM, Huang XT, Fu Y, Wu J, Ye CY, Li JL, Wu L, Gong Q, Zhao WM*, Zhang HY*. A novel caffeoyl triterpene attenuates cerebral ischemic injury with potent anti-inflammatory and hypothermic effects. J Neurochem. 2015;133:93-103.

morefold